Forbes digs into 'Pfizer's Nigerian nightmare'

As Pfizer negotiates a settlement with the Nigerian government in the long-running dispute over the Trovan drug trial there--and a U.S. federal appeals court considers whether Nigerian plaintiffs can sue the drugmaker here--Forbes delves into the background of the case, looking at documents and interviewing Pfizer officials, victims' families, and the FDA. An "unsettling look at the pitfalls of doing hurried drug trials in Third World countries," the story could be a cautionary tale for drugmakers conducting an increasing amount of research in the developing world. Report